AL 4 1A1
Alternative Names: AL-4-1A1Latest Information Update: 06 Sep 2023
At a glance
- Originator Allosterix Pharma
- Class Small molecules
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Dry eyes; Rheumatoid arthritis
Highest Development Phases
- Discontinued Dry eyes; Rheumatoid arthritis
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Rheumatoid arthritis in Israel (PO) (Allosterix Pharma pipeline, September 2023)
- 06 Sep 2023 Discontinued for Dry eyes in Israel (PO) (Allosterix Pharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (PO)